Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a ...

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month average ...

Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue ...